Biotech News

Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting

Elicio Therapeutics, Inc. (ELTX)Elicio Therapeutics, Inc.Clinical readout

Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer’s (“SITC”) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.

Related news

ELTXElicio Therapeutics, Inc.2026-10-23 13:00 EST

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

IMCRImmunocore Holdings plc2026-10-29 13:00 EST

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

ELVNEnliven Therapeutics2026-10-14 20:30 EST

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

CGEMCullinan Therapeutics, Inc.2026-10-08 11:00 EST

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

NRIXNurix Therapeutics2026-11-03 21:01 EST

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

KURAKura Oncology2026-10-13 11:30 EST

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

Elicio Therapeutics, Inc.

Lymph-Node-Targeted Immunotherapies Elicio Therapeutics develops immunotherapies designed to traffic directly to lymph nodes, where immune responses are coordinated. Its amphiphile technology links therapeutic payloads to albumin for delivery into lymphatic tissue. ELI-002 7P ELI-002 7P is an off-the-shelf therapeutic cancer vaccine...

Recent company news

Stock data

Close
1.50 USD
Market cap
219.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States